Macrogenics Inc (NAS:MGNX)
$ 4.365 -0.755 (-14.75%) Market Cap: 273.39 Mil Enterprise Value: 170.46 Mil PE Ratio: 0 PB Ratio: 3.02 GF Score: 68/100

MacroGenics Inc at American Society of Clinical Oncology Conference Call Transcript

Jun 04, 2019 / 06:30PM GMT
Release Date Price: $15.58 (-16.73%)
Operator

Good day, ladies and gentlemen, and welcome to the MacroGenics ASCO 2019 Conference Call. (Operator Instructions) As a reminder, this call is being recorded.

I would now like to introduce your host for today's conference, Anna Krassowska, Investor Relations. You may begin.

Anna Krassowska
MacroGenics, Inc. - VP of IR & Corporate Communications

Thank you, operator. Good afternoon, and welcome to the MacroGenics conference call to review the margetuximab Phase III SOPHIA study presentation at the American Society of Clinical Oncology or ASCO annual meeting and discuss ongoing and future clinical development plans for the program.

The presentation that accompanies this conference call is available under the Investors tab on our website at www.macrogenics.com. You can listen to this conference call live via webcast on the website where it will be archived for 30 days beginning approximately 2 hours after the call is completed.

Before we begin, I would like to alert

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot